Loken M K, Clay M E, Carpenter R T, Boudreau R J, McCullough J J
Clin Nucl Med. 1985 Dec;10(12):902-11. doi: 10.1097/00003072-198512000-00024.
Following the introduction of In-111 oxine as a label for blood cells by McAffee and Thakur in 1976, these procedures have become increasingly important in the practice of nuclear medicine. Of particular interest are studies involving the use of labeled leukocytes for the detection of focal infection. The clinical utility of labeled platelets is less well developed, although the use of platelets to detect the formation of thrombi in blood vessels and on vascular grafts and prostheses is gaining prominence. This report summarizes the techniques presently employed at the University of Minnesota for the labeling of blood products, and their clinical use. Consideration also is given to the desired expertise and cost factors involved in the labeling of leukocytes and platelets.
1976年麦卡菲和塔库尔将铟-111奥克辛用作血细胞标记物后，这些程序在核医学实践中变得越来越重要。特别值得关注的是涉及使用标记白细胞检测局灶性感染的研究。标记血小板的临床应用发展较少，尽管使用血小板检测血管内及血管移植物和假体上血栓形成的应用正日益突出。本报告总结了明尼苏达大学目前用于标记血液制品的技术及其临床应用。同时还考虑了标记白细胞和血小板所需的专业知识和成本因素。
